(3S,6R,9S,12R,15S,18R,21S,24R)-3,9,15,21-Tetraisobutyl-4,6,10,16,18,22-hexamethyl-12,24-bis[4-(4-morpholinyl)benzyl]-1,7,13,19-tetraoxa-4,10,16,22-tetraazacyclotetracosane-2,5,8,11,14,17,20,23-octone(CAS: 155030-63-0)

This compound is subject to the Chemicals of Very High Concern (SVHC) list under REACH regulations in the EU. It must comply with GHS (Global Harmonized System of Classification and Labelling of Chemicals) for classification and labeling. In the USA, it must adhere to FDA and EPA guidelines for the registration of new active ingredients in pharmaceuticals and pesticides respectively.

Alternatives include morpholine derivatives with different substituents, such as morpholine or piperidine, which can serve as precursors or intermediates in similar synthesis pathways. Commonly used reagents like morpholine or piperidine-based compounds can be considered as substitutes in certain chemical reactions.

Research trends are primarily focused on understanding its potential applications in drug discovery and synthesis of complex molecules. Market trends indicate increasing interest in organic synthesis and pharmaceutical intermediates, driven by advancements in medicinal chemistry and the need for novel therapeutic agents.

Waste containing this compound should be handled by collecting it in appropriate containers and ensuring proper containment to prevent spillage. It should be disposed of through professional waste disposal services, following local and international regulations. Environmental protection measures include minimizing exposure to air, water, and soil, and ensuring that waste is incinerated or treated in a manner that does not release harmful substances into the environment.